52 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
3 Dividend-Paying Stocks for Investors to Buy to Fight Off Market Uncertainty http://www.zacks.com/stock/news/747608/3-dividend-paying-stocks-for-investors-to-buy-to-fight-off-market-uncertainty?cid=CS-ZC-FT-stocks_in_the_news|major_headlines-747608 Feb 03, 2020 - Check out these three dividend-paying stocks that investors might want to buy to help combat coronavirus-based market pullback fears...
Top Research Reports for Netflix, Eli Lilly & United Parcel Service http://www.zacks.com/research-daily/750463/top-research-reports-for-netflix-eli-lilly-united-parcel-service?cid=CS-ZC-FT-research_daily-750463 Feb 05, 2020 - Top Research Reports for Netflix, Eli Lilly & United Parcel Service
Sanofi (SNY) Q4 Earnings Top, Sales Miss, Dupixent Strong http://www.zacks.com/stock/news/752611/sanofi-sny-q4-earnings-top-sales-miss-dupixent-strong?cid=CS-ZC-FT-analyst_blog|earnings_article-752611 Feb 06, 2020 - Sanofi (SNY) reports mixed fourth-quarter results with strong Specialty Care and Vaccines sales but soft Consumer Healthcare sales
Teva (TEVA) to Report Q4 Earnings: What's in the Cards? http://www.zacks.com/stock/news/754447/teva-teva-to-report-q4-earnings-whats-in-the-cards?cid=CS-ZC-FT-analyst_blog|earnings_preview-754447 Feb 07, 2020 - Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q4 sales.
Lilly Reports Disappointing Data on Alzheimer's Candidate http://www.zacks.com/stock/news/760082/lilly-reports-disappointing-data-on-alzheimers-candidate?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-760082 Feb 11, 2020 - Eli Lilly's (LLY) Alzheimer's disease drug, solanezumab, fails to meet primary endpoint in a phase II/III investigator-led study.
Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails http://www.zacks.com/stock/news/765605/pharma-stock-roundup-abbv-agn-post-q4-results-another-alzheimers-study-fails?cid=CS-ZC-FT-analyst_blog|stock_roundup-765605 Feb 14, 2020 - AbbVie (ABBV) and Allergan (AGN) announce Q4 results.
3 Biotech Stocks With a Lot to Prove at ASH 2019 https://www.fool.com/investing/2019/12/02/3-biotech-stocks-with-a-lot-to-prove-at-ash-2019.aspx?source=iedfolrf0000001 Dec 02, 2019 - These companies have some important presentations scheduled for the last big oncology conference of the year.
Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study http://www.zacks.com/stock/news/668756/pharma-stock-roundup-mrk-sny-to-buy-cancer-firms-lly-starts-new-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|stock_roundup-668756 Dec 13, 2019 - This week two deals grab headlines in the pharma space. Merck (MRK) offers to buy ArQule for $2.7 billion while Sanofi (SNY) signs a definitive deal to purchase Synthorx for $2.5 billion
Lilly's Cyramza Gets CHMP Recommendation for First-Line NSCLC http://www.zacks.com/stock/news/673027/lillys-cyramza-gets-chmp-recommendation-for-first-line-nsclc?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-673027 Dec 16, 2019 - Lilly's (LLY) regulatory application seeking approval for cancer drug, Cyramza, in combination with erlotinib for treating EGFR-mutated NSCLC in first-line setting gets positive CHMP opinion for approval in EU.
Story Stocks: Eli Lilly's new product growth has pharmaceutical company feeling revived (LLY) https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=NS20191217082045StoryStocks Dec 17, 2019 - Over the past couple of years, patents have expired on a few of Eli Lilly's (LLY) key drugs, most no

Pages: 123456

<<<Page 3>